1. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

   • Christian Jackisch
   • Federico Manevy
   • Jason Shafrin

   Commentary Open access 05 January 2022 Pages: 833 - 844

   

2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review

   • Shaline Rao

   Review Open access 09 December 2021 Pages: 845 - 861

   

3. Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence

   • Yongmei Wang
   • Fanbo Jing
   • Haibo Wang

   Review 06 January 2022 Pages: 862 - 891

   

4. An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach

   • Marjanne A. Piena
   • Sonja Kroep
   • Ben A. van Hout

   Original Research Open access 18 November 2021 Pages: 892 - 908

   

5. Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach

   • Marjanne A. Piena
   • Sonja Kroep
   • Ben A. van Hout

   Correction 08 January 2022 Pages: 909 - 909

6. Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan

   • Kuan-Yuan Chen
   • Kang-Yun Lee
   • Po-Hao Feng

   Original Research 15 December 2021 Pages: 910 - 922

   

7. Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study

   • Gouranga Sarkar
   • Vijay B. Gaikwad
   • Suyog Mehta

   Original Research 17 December 2021 Pages: 923 - 942

   

8. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States

   • Jan Sieluk
   • Yan Song
   • Kim Marie Hirshfield

   Original Research 17 December 2021 Pages: 943 - 958

   

9. Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

   • Jeffrey Frankel
   • David Staskin
   • Cynthia J. Girman

   Original Research Open access 18 December 2021 Pages: 959 - 970

   

10. Measuring Burden of Illness in Phenylketonuria (PKU): Development of the PKU Symptom Severity and Impacts Scale as a Robust Patient-Reported Outcome

    • Jennifer Quinn
    • Alexandros Georgiadis
    • Elaina Jurecki

    Original Research Open access 18 December 2021 Pages: 971 - 991

    

11. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data

    • Manami Yoshida
    • Ryosuke Tateishi
    • Ataru Igarashi

    Original Research Open access 20 December 2021 Pages: 992 - 1003

    

12. The Epidemiology of Persons Living with Fontan in 2020 and Projections for 2030: Development of an Epidemiology Model Providing Multinational Estimates

    • Leandra Plappert
    • Susan Edwards
    • Angela De Martini

    Original Research Open access 22 December 2021 Pages: 1004 - 1015

    

13. Individualized HbA_1c Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey

    • Dominik Lautsch
    • Robert Boggs
    • Victoria Higgins

    Original Research Open access 24 December 2021 Pages: 1016 - 1032

    

14. Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis

    • Jill Davis
    • Rubeen Israni
    • Eric Q. Wu

    Original Research Open access 27 December 2021 Pages: 1033 - 1044

    

15. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework

    • Bryony Langford
    • Alex Diamantopoulos
    • Michael Baldwin

    Original Research Open access 27 December 2021 Pages: 1045 - 1054

    

16. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study

    • Kurt de Vlam
    • Adrien Nzeusseu Toukap
    • Rik Lories

    Original Research Open access 03 January 2022 Pages: 1055 - 1067

    

17. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study

    • Pierre-Dominique Ghislain
    • Jo Lambert
    • Siegfried Segaert

    Original Research Open access 03 January 2022 Pages: 1068 - 1080

    

18. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use

    • Michael Kreuter
    • Toby M. Maher
    • Vincent Cottin

    Brief Report Open access 22 December 2021 Pages: 1081 - 1095

    

19. Correction to: Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

    • Shu Hashimoto
    • Ryoko Sorimachi
    • Masakazu Ichinose

    Correction 06 January 2022 Pages: 1096 - 1099